Abstract
A new series of NSAIDs in which aspirin is joined by an ester linkage to furoxan moieties, with different ability to release NO, were synthesized and tested for NO-releasing, antiinflammatory, antiaggregatory, and ulcerogenic properties. Related furazan derivatives, aspirin, its propyl ester, and its gamma-nitrooxypropyl ester were taken as references. All the products described present an antiinflammatory trend, maximized in derivatives 12, 16, and 17, they are devoid of acute gastrotoxicity, principally due to their ester nature, and show an antiplatelet activity primarily determined by their ability to release NO. They do not behave as aspirin prodrugs in human serum.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Anti-Inflammatory Agents, Non-Steroidal / chemical synthesis*
-
Anti-Inflammatory Agents, Non-Steroidal / pharmacology
-
Anti-Inflammatory Agents, Non-Steroidal / toxicity
-
Aspirin / analogs & derivatives*
-
Aspirin / chemical synthesis*
-
Aspirin / pharmacology
-
Aspirin / toxicity
-
Edema / drug therapy
-
Esters
-
Gastric Mucosa / drug effects
-
Gastric Mucosa / pathology
-
Humans
-
Hydrogen-Ion Concentration
-
Hydrolysis
-
In Vitro Techniques
-
Male
-
Necrosis
-
Nitric Oxide / blood
-
Nitric Oxide Donors / chemical synthesis*
-
Nitric Oxide Donors / pharmacology
-
Nitric Oxide Donors / toxicity
-
Peptic Ulcer / chemically induced
-
Peptic Ulcer / pathology
-
Platelet Aggregation Inhibitors / chemical synthesis*
-
Platelet Aggregation Inhibitors / pharmacology
-
Platelet Aggregation Inhibitors / toxicity
-
Rats
-
Rats, Wistar
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Esters
-
Nitric Oxide Donors
-
Platelet Aggregation Inhibitors
-
Nitric Oxide
-
Aspirin